Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care
Introduction Several cardiovascular outcome trials have been conducted to assess the cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on cardiorenal outcomes in patients with type-2 diabetes (T2D). However, the strict requirements of randomised controlled tr...
Guardat en:
| Autors principals: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2025-01-01
|
| Col·lecció: | BMJ Open |
| Accés en línia: | https://bmjopen.bmj.com/content/15/1/e087790.full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|